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Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular
endothelialgrowthfactor(VEGF)hasbeenshowntoplayapivotalroleintheprogressionofovariancancerleadingtotheeventual
developmentofmalignantascites.Onthisbasis,agentsrenderingVEGFineﬀectivebyneutralizingVEGF(bevacizumab),blocking
itsreceptors(aﬂibercept),orinterferingwiththepostreceptorsignalingpathways(sunitinib)provideuswiththerationaltreatment
options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of
and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in diﬀerent
preclinical and clinical studies.
1.Introduction
Ovarian cancer is the sixth leading cancer diagnosed among
women in the world and the second most common gyne-
cologic cancer, comprising nearly 4% of all female cancers
[1, 2]. Due to lacking early warning signs and eﬀective
screening tools, approximately 75% of patients present with
late stage disease [3].
Conventional cytotoxic chemotherapy induces a large
proportion of responses in the ﬁrst-line treatment of
advanced ovarian cancer with response rates of 60–80%, but
thesubsequentrelapseanddeathwilldevelopinthemajority
of patients [4]. Most cases of advanced ovarian cancer will
show resistance to chemotherapy in spite of intensive
primary interventions. Targeting tumor vasculature has been
theoretically a focus of great interest in this regard due to not
only its vital role of conducting tumor blood supply, but also
its epithelial cells being more genetically stable than tumor
cells [5].
Reviewing the role of vascular endothelial growth factor
in ovarian cancer and the feasibility and possible role of
VEGF-targeted strategies in ovarian cancer treatment as well
as their promises and challenges is the aim of this article.
2. The Role of Angiogenesisin
OvarianPhysiology
Female reproductive cycle is intricately connected to the
coordinated action of angiogenic factors and steroid hor-
mones. Dominant follicles starting maturation in ovulatory
cycle are those with higher vascularity that eventually
synthesize the steroid hormones required for endometrial
development by turning into corpus luteum. This increased
vascularity continues during luteal phase to supply nutrients
and steroid precursors and helps to make active steroid
hormones accessible to the endometrium. Cyclical changes
in the level of vascular growth factors in diﬀerent stages of
menstrual cycle indicate the importance of angiogenesis in
ovarian physiology. Increased intrafollicular levels of VEGF
have been shown during the initial part of the ovulatory
cycle, with peak concentrations just before the start of the
luteal phase [6].2 Journal of Oncology
3. Tumor Angiogenesisand Its Role in
OvarianCancer
Like their normal counterparts, tumor cells are in crucial
need of a vascular system to satisfy their own requirements
of having access to oxygen and nutrients supply and waste
removal. Tumor angiogenesis is the mechanism required for
fulﬁlling these requirements, without which tumors fail to
grow beyond 1-2mm and may remain dormant [7].
Tumor-induced blood vessels possess ultrastructural
abnormalities,includinglackoffunctionalpericytes,dilation
and convolution, exceptional permeability, and vascular
walls being inﬁltrated by tumor cells [8].
In ovarian cancer, an imbalance between tumor levels
of pro- and antiangiogenic factors in favor of angiogenesis
activation occurs. It is indicated as increased proangiogenic
factors, including VEGF, ﬁbroblast growth factor (FGF),
platelet-derived growth factors (PDGFs), tumor necrosis
factor-alpha (TNF-α), angiopoietins and interleukins (IL-6,
IL-8), and decreased antiangiogenic factors, including
angiostatins and endostatins [9]. It has been indicated that
the modulation of angiogenic pathways in ovarian surface
epithelium may alter its tumorigenicity [10]. Although
microvessel density (MVD) in ovarian cancer has correlated
with extent of disease and, inversely, with overall survival
(OS)orprogressionfreesurvival(PFS)[11],diﬀerentstudies
have reported contradictory data regarding a convincing
correlation between MVD and ovarian cancer prognosis
[12–14].
4.The Role of VascularEndothelialGrowth
Factor in OvarianCancer
VEGF promotes proliferation, migration, stabilization, and
survival of endothelial cells and mobilization of endothelial
progenitor cells from bone marrow and yields a direct eﬀect
o nt u m o rc e l lp r o l i f e r a t i o na n di n v a s i v e n e s sa sw e l l[ 9, 15].
VEGF, formerly known as vascular permeability factor
(VPF), has also a key role in enhancing vascular permeability
[9]. In advanced ovarian cancer, VEGF-induced hyper-
permeability of peritoneal blood vessels and subsequent
intraperitoneal hyperosmolarity caused by leaked plasma
proteins will lead to malignant ascites, a prevalent, debil-
itating manifestation of the late-stage disease indicating
disease progression and treatment failure [16]. Moreover,
some leaked proteins such as plasminogen activator, matrix
metalloproteinases, interstitial collagenases, and gelatinase-
A provide space for new cell growth through degrading
extracellular matrix while ﬁbrinogen facilitates microvascu-
lar growth [15].
VEGF induces tumor angiogenesis in a way very similar
to how it promotes physiological angiogenesis [17]. As a
mitogen for vascular endothelial cells, VEGF promotes new
blood vessels formation, and as a survival factor, it stabilizes
new, poorly formed tumor vasculature and inhibits endothe-
lial cell apoptosis, resulting in sustained tumor growth [15].
It has been demonstrated that VEGF inhibition normalizes
tumor vessels and enhances oxygen and chemotherapeutics
delivery to the tumoral tissue [6].
Investigations show that VEGF also contributes to tumor
metastasis by inducing the formation of structurally abnor-
mal blood vessels that can be easily penetrated by neo-
plastic cells [17]. Moreover, increased expression of matrix
metalloproteinase-2 by VEGF can enhance the invasiveness
of tumor cells [9].
In addition to its paracrine eﬀect on tumor vascular
endothelial cells, VEGF has been found to have an autocrine
eﬀect by interesting discovery of VEGF receptors on tumor
cells [18, 19]. However, the functional signiﬁcance of this
ﬁnding and the underlying cellular processes of VEGF/
VEGFR autocrine loop are being studied. A functional role
for VEGFR-2 and a distinct VEGFR-2-mediated pathway
promoting tumor growth in ovarian cancer have been
demonstrated [20].
VEGF expression in ovarian cancer has been evaluated in
several studies. Some degree of VEGF expression in all exam-
ined ovarian cancer specimens as well as signiﬁcantly higher
levels of VEGF expression in tumor specimens compared to
benign ovarian tissue have been reported [21]. A correlation
between increased titers of VEGF in cytosolic fractions from
tumor specimens and increased stage and decreased survival
was found as well. In early stage ovarian cancers, increased
VEGF expression has been shown to correlate with worse
disease-free survival (DFS) and poor OS [22]. In addition,
higher serum levels of VEGF associated with ovarian cancer
were considered as an independent risk factor and a prog-
nosticparameterforascites,moremetastasis,advanced-stage
disease, and decreased survival [23, 24]. VEGF upregulation
enhanced the invasiveness of ovarian cancer cells in vitro
[25] and VEGF blockade in animal models of ovarian
cancer inhibited ascites formation and slowed the tumor
growth [26]. Several retrospective clinical studies in ovarian
cancer have also demonstrated that intratumoral VEGF and
VEGFR-2 expression and VEGF gene polymorphisms are
independent poor prognostic factors [27–29]. Overexpres-
sion of neuropilin, a coreceptor enhancing VEGF signaling,
has also been found in ovarian cancer [30, 31].
5.Anti-VEGFAgents inOvarianCancer:
PreviousandCurrentStudies
Known to play a key role in normal ovarian physiology and
in ovarian cancer, VEGF signaling axis has been an attractive
target in antiangiogenic approaches. Agents that target this
pathway are currently in clinical development for ovarian
cancer (Table 1).
5.1. VEGF Ligand Binders
5.1.1. Bevacizumab. Bevacizumab is a recombinant human-
ized VEGF monoclonal antibody derived from its murine
equivalent A4.6.1. It directs against all active isoforms of
VEGF and prevents them from binding to VEGFR [32].
Known as the ﬁrst anti-VEGF agent approved by the Food
and Drug Administration (FDA) in 2004 for clinical use in
colorectal cancer, bevacizumab has also been the ﬁrst anti-
VEGF agent to be evaluated in the treatment of ovarian
cancer [4, 33].Journal of Oncology 3
Table 1: Anti-VEGF agents in clinical development for ovarian cancer.
Mechanism(s) of action Drug Molecular target(s)
VEGF ligand binders Bevacizumab VEGF A (all isoforms)
Aﬂibercept (VEGF trap) VEGF A and B, PlGF
VEGF receptor tyrosine kinase inhibitors
Ramucirumab VEGFR2
Cediranib VEGFR1-3, c-Kit, PDGFR-β
Semaxanib VEGFR2
Multiple-receptor tyrosine kinase inhibitors
Sunitinib VEGFR1-3, Flt-3, PDGFR-α,P D G F R - β, c-Kit, CSF-1R, RET
Sorafenib VEGFR1-3, PDGFR-β, Flt-3, c-Kit, Raf-1
Vatalanib VEGFR1-3, PDGFRβ, c-Kit, c-Fms
Intedanib (BIBF1120) VEGFR1-3, PDGFR-α,P D G F R - β,F G F R 1 - 3
Pazopanib VEGFR1-2, PDGFR-β,c - K i t
Motesanib VEGFR1-3, PDGFR, c-Kit
Vandetanib VEGFR2-3, EGFR
AEE788 VEGFR, EGFR
VEGF: vascular endothelial growth factor, PlGF: placenta growth factor, VEGFR: vascular endothelial growth factor receptor, PDGFR: platelet-derived growth
factor receptor, CSF-1R: colony stimulating factor 1 receptor, EGFR: epidermal growth factor receptor.
Table 2: Clinical trials of single-agent therapy with bevacizumab in ovarian cancer.
Trial number Phase Stage of the disease Number
of patients CR PR MPFS (m) MOS (m)
Completed
NCT00022659 (GOG170D) [37]I I Persistent or recurrent
EOC or PPC 62 3% 18% 4.7 17
NCT00097019 (AVF2949g) [38] II Recurrent EOC or PSC 44 0 15.9% 4.4 10.7
Ongoing
NCT00866723(08-323)∗ II Relapse after bevacizumab
maintenance therapy 32 N/A N/A N/A N/A
EOC: epithelial ovarian cancer, PPC: primary peritoneal cancer, PSC: peritoneal serous carcinoma, CR: complete response, PR: partial response, MPFS:
median progression-free survival, MOS: median overall survival, m: months, N/A: nonaccessible.
∗Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.
Preclinical Data. Several experiments have shown that neu-
tralizing VEGF by bevacizumab has marked antitumor
eﬀects. In 1998, Mesiano et al. examined the role of
bevacizumab in immunodeﬁcient mice with ovarian cancer
and demonstrated that bevacizumab signiﬁcantly inhibited
subcutaneoustumorgrowth,partiallyinhibiteditsintraperi-
toneal growth, and completely prevented ascites production
[34]. Hu et al. reported additive or synergistic eﬀects of
this antibody in combination with paclitaxel in ovarian
tumor xenograft studies including enhanced sensitivity to
paclitaxel and marked reduction of tumor growth and
ascites formation [35]. Those eﬀects have been conﬁrmed by
Mabuchi et al. using bevacizumab in combination with cis-
platin. Moreover, they showed that maintenance treatment
with bevacizumab could inhibit recurrence and signiﬁcantly
prolong survival in vivo [36].
Clinical Data
(i) As a Single Agent. The initial clinical evidence regarding
the activity of bevacizumab for ovarian cancer, mainly in
recurrent, heavily pretreated patients, was ﬁrst reported by
Monk et al. in 2005 [42]. Since then, bevacizumab has been
examined in two prospective phase II trials as a single agent
for patients with recurrent ovarian cancer, predominantly
platinum-resistant disease as shown in Table 2 [37, 38].
(ii) Combined with Chemotherapy
RetrospectiveStudies. In2006,Wrightetal.reportedapartial
response (PR) of 35% and a median PFS of 5.6 months
in a retrospective analysis of 23 patients with recurrent
platinum-refractory epithelial ovarian cancer treated with
a combination of bevacizumab with some cytotoxic agents
including cyclophosphamide, 5-ﬂuorouracil, docetaxel, and
gemcitabine and liposomal doxorubicin [43]. In another
study on 35 patients with recurrent ovarian cancer who
received a combination of gemcitabine, platinum, and
bevacizumab, Richardson et al. reported an overall response
rate (ORR) of 78%, a complete response (CR) of 48%, and
a median PFS of 12 months [44] .I nas t u d yb yC h u r ae t
al. on 15 heavily pretreated patients with recurrent ovarian
cancer, a combination of bevacizumab and metronomic oral
cyclophosphamide resulted in a CR of 13.3% and a PR of
40% [45]. O’Malley and colleagues have recently reported
the results of a study on two groups of heavily pretreated4 Journal of Oncology
Table 3: Completed clinical trials of bevacizumab combined with chemotherapy in ovarian cancer.
Trial number Phase Chemotherapy Stage of the disease Number
of patients Outcomes
NCT00127920 (AV53206s) [39] II Carboplatin + paclitaxel Newly diagnosed stage
III/IV 20 CR: 30%
PR: 50%
NCT00072566 (NCI-5789) [40] II Metronomic cyclophosphamide Platinum-sensitive
recurrent 70
CR: 0
PR: 24%
MPFS: 7.2 (m)
MOS: 16.9 (m)
NCT00129727 (OVCA) [41]I I
Carboplatin + paclitaxel +
bevacizumab + maintenance
bevacizumab
Newly diagnosed stage ≥
IC 62
CT:
CR: 56%
PR: 22%
Ca-125:
CR: 89%
PR: 7%
NCT00343044 (3040200,
AVF3648s)∗ II Topotecan
Platinum-resistant
recurrent EOC, PPC,
FTC
N/A N/A
CR: complete response, PR: partial response, MPFS: median progression-free survival, m: months, MOS: median overall survival (months), EOC: epithelial
ovarian cancer, PPC: primary peritoneal cancer, FTC: fallopian tube cancer.
∗Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.
patients with recurrent ovarian cancer: 29 patients treated
with weekly paclitaxel as compared to 41 patients treated
with weekly paclitaxel and biweekly bevacizumab. They have
indicated that addition of bevacizumab to weekly paclitaxel
has resulted in a signiﬁcant increase in PFS with a trend
towards improved OS [46].
Clinical Trials. To date, three clinical trials on bevacizumab
combined with chemotherapy have been published. A sum-
mary of the outcome from these studies is listed in Table 3
[39–41].
Bevacizumabiscurrentlybeingevaluatedincombination
with various chemotherapy regimens brieﬂy described in
Table 4.
The results from GOG218 (NCT00262847) have been
reported at the 2010 American Society of Clinical Oncology
(ASCO) annual meeting. Based on their report, there was
a 3.8-month improvement in PFS (14.1 months for the
maintenance regimen of BEV as opposed to 10.3 months
for standard chemotherapy) [47]. Initial results of ICON7
(NCT00483782) trial presented in October 2010 showed
that the addition of bevacizumab to standard chemotherapy
resulted in 15% improvement in PFS at 12 months, 1.7-
month improvement in median PFS, and 1.5-month overall
improvement in PFS. Treatment eﬀect is numerically greater
in advanced-stage patients with no new side eﬀects [48].
Side Eﬀects. Being generally well tolerated, the most com-
mon bevacizumab-attributable side eﬀect, hypertension, can
be medically controlled. However, gastrointestinal perfora-
tion and thromboembolic disease were documented as two
major complications [33], and the overall rate of bowel per-
forationinovariancancerseemstobehigherthanothersolid
tumors. Other common adverse events include proteinuria,
bleeding, and wound-healing complications [9]. Preliminary
analysis of a prospective study evaluating the safety and
eﬃcacy of bevacizumab in cancer patients has demonstrated
severe pulmonary and nonpulmonary hemorrhage as an
associated risk with a rate of 0.5% and 1.2%, respectively
[49]. Also, a meta-analysis of randomized controlled trials
has recently reported that bevacizumab may signiﬁcantly
increase the risk of serious hemorrhage in cancer patients
[50]. Reversible posterior leukoencephalopathy syndrome
(RPLS), tracheoesophageal ﬁstulae [6], spontaneous nasal
septal perforation, and erosive osteoarthritis are signiﬁcant,
but rare, complications [9]. In a recent meta-analysis
of published randomized controlled trials, bevacizumab
in combination with chemotherapy or biological therapy,
compared with chemotherapy alone, was associated with
increased treatment-related mortality [51].
5.1.2. Aﬂibercept (VEGF Trap). Aﬂibercept is a soluble decoy
receptor based on VEGF receptor-1 and VEGF receptor-
2 fused to the Fc portion of human immunoglobulin G1
that binds and inactivates some members of VEGF family,
including VEGF-A, VEGF-B, and placental growth factor
(PlGF) [4].
Preclinical Data. In 2003, Byrne et al. reported that single-
agent aﬂibercept signiﬁcantly reduced both ascites and
tumor burden in experimental ovarian cancer models [26].
This preclinical eﬃcacy was further validated by Hu et al.
who showed a 98% reduction in tumor burden, inhibition of
ascites, and prolonged survival in a mouse model of human
ovarian cancer treated by aﬂibercept plus paclitaxel [52].
Clinical Data. Aﬂibercept has been investigated in some
clinical studies described in Table 5.
Side Eﬀects. Based on the initial results of their study, Tew
et al.reportedthatthemostcommongrade3-4sideeﬀectsofJournal of Oncology 5
Table 4: Ongoing clinical trials of bevacizumab combined with chemotherapy in ovarian cancer.
Trial number Phase Chemotherapy Stage of the disease
Number of
patients
(estimated)
NCT00127920 (AV53206s) II Carboplatin + paclitaxel + bevacizumab Newly diagnosed stage III/IV 20
NCT00296816 (TEACO) II Oxaliplatin + docetaxel + bevacizumab Newly diagnosed stage IB-IV 145
NCT00511992 (AVF3953) II Paclitaxel + cisplatin + bevacizumab
followed by bevacizumab Newly diagnosed stage II-III 20
NCT00588237 (06-064) II Paclitaxel + cisplatin + bevacizumab Initial treatment of optimal stage II
or III (adjuvant) 42
NCT00267696 (2005CO073) II Gemcitabine + carboplatin +
bevacizumab Platinum-sensitive recurrent 45
NCT00698451 (CR015094) II Carboplatin + liposomal doxorubicin +
bevacizumab Platinum-sensitive recurrent 54
NCT00418093 (04-356) II Oxaliplatin + gemcitabine +
bevacizumab Platinum-sensitive recurrent 40
NCT00868192 (08-0508) II Pemetrexed + bevacizumab Recurrent having failed platinum-
and taxane-based regimens 25
NCT00504257 (MCC-14920,
MCC-105366c) II Docetaxel + bevacizumab Platinum-resistant recurrent 44
NCT00744718 (2008-000878-20,
S-20080033) II Carboplatin + bevacizumab Platinum-resistant recurrent 30
NCT00846612 (06-948,
AVF3910s) II Liposomal doxorubicin + bevacizumab Platinum-resistant recurrent 48
NCT00856180 (08-148) II Cyclophosphamide + bevacizumab Platinum-resistant recurrent 20
NCT00407563 (ALSSOPR0501) II Abraxane (protein-bound paclitaxel ) +
bevacizumab Platinum-resistant recurrent 48
NCT00937560 (MO22225) II Carboplatin + paclitaxel + bevacizumab Previously untreated, but initial
surgery 188
NCT00583622 (2007-0368) II Gemcitabine + docetaxel + melphalan +
carboplatin + bevacizumab
Second or later complete remission,
or untreated or refractory relapse to
platinum treatment or lack of
response to salvage treatment
40
NCT00483782 (ICON7) III Carboplatin + paclitaxel ± bevacizumab Newly diagnosed 1520
NCT00262847 (GOG218) III
Carboplatin + paclitaxel versus
carboplatin + paclitaxel + bevacizumab ±
maintenance bevacizumab
Newly diagnosed, previously
untreated stage III or IV 2000
NCT00565851 (GOG213) III
Carboplatin + paclitaxel ± bevacizumab
followed by bevacizumab and secondary
cytoreduction surgery
Platinum-sensitive recurrent 660
NCT00434642 (OCEANS,
AVF4095g) III Carboplatin + gemcitabine ±
bevacizumab Platinum-sensitive recurrent 487
NCT00652119 (2007-0223) N/A Carboplatin + paclitaxel + bevacizumab Newly diagnosed stage III/IV 46
∗Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.
aﬂibercept therapy were hypertension (9%) and proteinuria
(4%). Other adverse events included headache, fatigue, dys-
phonia, nausea, asthenia, diarrhea, renal dysfunction, and a
remarkably lower incidence of bowel perforation (1%) [53].
5.2. VEGF Receptor Tyrosine Kinase Inhibitors
5.2.1. Ramucirumab (IMC-1121B). Ramucirumab is a fully
humanized monoclonal antibody that speciﬁcally and
potently inhibits VEGFR-2 [9]. On the basis of in vitro
studies, ramucirumab has been investigated in mouse
xenograft models of human ovarian cancer resulting in
reduced tumor growth, increased apoptosis, and decreased
tumor microvessel proliferation and density [55]. Being
observedinseveralphaseIclinicaltrialsinsolidtumors[56],
ramucirumab is currently being assessed in a phase II trial
as a monotherapy in patients with persistent or recurrent
epithelial ovarian cancer [57].
Ramucirumab has shown safety in phase I trials. Two
dose-limiting toxicities including hypertension and deep
vein thrombosis were noted by Spratlin et al. in a phase I trial
[58].6 Journal of Oncology
Table 5: Clinical trials for VEGF trap in ovarian cancer.
Trial Phase Stage of the disease Results
Single agent
NCT00327171 (ARD6122,
AVE0005)—Completed II
Platinum-resistant and topotecan and/or
liposomal doxorubicin-resistant
advanced ovarian cancer
Preliminary results from 162 randomized
patients showed a partial response of
11%. [53]
NCT00396591 (ARD6772)—Completed II
Platinum-resistant and topotecan and/or
liposomal doxorubicin-resistant
advanced ovarian cancer with recurrent
symptomatic malignant ascites
First results demonstrated the eﬃcacy of
two weekly IV aﬂibercept in prolonging
the time to repeat paracentesis in eight
out of ten evaluable patients. [54]
NCT00327444 (EFC6125)—Completed II/III
Platinum-resistant and topotecan and/or
liposomal doxorubicin-resistant
advanced ovarian cancer with recurrent
symptomatic malignant ascites
Results are awaited
Combination with chemotherapy
(docetaxel)
NCT00436501
(MDA-2006-0329)—ongoing I/II
Recurrent or persistent epithelial ovarian,
primary peritoneal, or fallopian tube
cancer
Ongoing
IV: Intravenous, VEGF: Vascular endothelial growth factor.
∗Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.
5.2.2. Cediranib (AZD2171). This is a novel oral tyrosine
kinaseinhibitorthatselectivelyblocksVEGFR1-3,PDGFR-β,
and c-Kit [4]. Cediranib has been shown to inhibit the
growth of human tumor xenografts, including ovarian
cancer, in a dose-dependent manner [59]. In 2009, the
results of a phase II study of single-agent cediranib for
recurrent ovarian, peritoneal, or tubal cancer were reported
by Matulonis et al. Overall clinical beneﬁt for the intent-
to-treat (ITT) population was 30%; 17% patients achieved
a partial response representing the overall response rate.
Thirteen percent of patients had stable disease. No patients
had a complete response [60]. In another phase II trial by
Hirte et al., response rate was 41% and 29% for platinum-
sensitive and platinum-resistant disease, respectively [61].
Other phase II and III trials [62–64] are ongoing to
investigate its eﬃcacy as single agent or in combination
therapy, among which is ICON6, a three-arm randomized
placebo-controlled phase III trial, investigating cediranib in
combination with platinum-based chemotherapy and as a
single-agent maintenance therapy in patients with platinum
sensitive relapsed ovarian cancer [64].
In both above-mentioned phase II trials, hypertension
and fatigue were the most common grade 3 toxicities.
Other reported adverse events were central nervous system
hemorrhage, elevated lipase, hypertriglyceridemia, diarrhea,
anorexia, vomiting, hyponatremia, oral cavity pain, nau-
sea, constipation, abdominal pain, headache, and hypothy-
roidism [61, 65].
5.2.3. Semaxanib (SU5416). Potent and selective synthetic
inhibitor of VEGFR-2, semaxanib inhibits tyrosine kinase
catalysis, tumor vascularization, and growth of diﬀerent
tumor types [66]. In a study by Holtz et al., semaxanib
yielded reduced tumor growth and microvessel density in
mouse models of ovarian cancer with high VEGF expression.
Based on its combination with metronomic paclitaxel, they
also provided the ﬁrst evidence that the interactions between
low-dosechemotherapyandantiangiogenictherapycouldbe
aﬀectedbytumorVEGFexpressionastheyobservedadditive
eﬀects only in tumors with low VEGF expression [67]. A
phase I study of semaxanib in combination with carboplatin
in patients with platinum-refractory ovarian cancer has been
done [68].
5.3. Multiple-Receptor Tyrosine Kinase Inhibitors
5.3.1. Sunitinib (SU11248). Sunitinib is an orally bioavail-
able multityrosine kinase inhibitor that blocks VEGFR1-3,
Flt-3, PDGFR-α, PDGFR-β, c-Kit, CSF-1R, and RET with
proven antitumor activity in renal cell carcinoma and
imatinib-resistant or -intolerant gastrointestinal stromal
tumor (GIST) [4]. Its eﬀectiveness as a single agent in
recurrent or advanced ovarian cancer was proved by Bauer-
schlag et al. in an ovarian cancer xenograft mouse model,
in which the drug signiﬁcantly suppressed tumor growth
and peritoneal metastases, and also remarkably reduced
microvessel density count [69].
Having similar gene proﬁle to renal cell carcinoma
(RCC), recurrent or refractory ovarian clear cell adeno-
carcinoma—a biological subtype of epithelial ovarian
cancer—may beneﬁt from this agent. In one case report of a
60-year-old woman with ovarian clear cell adenocarcinoma
(OCCA), sunitinib resulted in stable disease as ﬁfth-line
therapy, decreased CA125 and cystic degeneration of liver
metastasis [70]. Based on the promise shown in diﬀerent
phaseI,II,andIIIstudiesofsunitinibinanumberofcancers,
four phase II trials of sunitinib as single-agent therapy in
ovarian cancer are being pursued [71–74]. One of thoseJournal of Oncology 7
is NCT00388037, ﬁrst results of which have demonstrated
single-agent sunitinib activity and tolerability in advanced
ovarian cancer with partial response in 2 and stable disease
in 10 among 17 patients [74].
Both on-target and oﬀ-target adverse eﬀects including
fatigue, diarrhea, dyspepsia, hypertension, hand-foot syn-
drome, nausea, anorexia, stomatitis, neutropenia, thrombo-
cytopenia, lipase elevations, and hypothyroidism are men-
tioned as typical side eﬀects of sunitinib in other diseases
[9, 75].
5.3.2. Sorafenib (Bay43-9006). Sorafenib is an oral multitar-
geted tyrosine kinase inhibitor that predominantly inhibits
Raf-1—which is vital for cell proliferation—and can block
VEGFR1-3, PDGFR-β, Flt-3, and c-Kit [9]. In a study by
Matsumura et al., sorafenib was shown to have antitumor
eﬀect against ovarian clear cell carcinoma (OCCC) as it
inhibited tumor growth in nude mice and signiﬁcantly
reduced tumor size [76]. In a phase I study of sorafenib in
patients with ovarian cancer, 50% of them showed evidence
of stable disease [77]. In another phase I trial, sorafenib
in combination with bevacizumab demonstrated durable
partial disease responses in 6 of 13 ovarian cancer patients
recruited [6]. In a phase II trial in patients suﬀering from
persistent or recurrent ovarian cancer, partial response was
seen in 3% of patient evaluated while 20% had stable disease
more than 6 months [78]. Another study of intermittent
sorafenib dosing with bevacizumab has promising clinical
activity and less sorafenib dose reduction and side eﬀects
in advanced ovarian cancer [79]. Six clinical trials of
sorafenib combined with other agents are now underway
[80–85].
Although diarrhea and hand-foot syndrome are more
prevalent than other side eﬀects, alopecia, anorexia, and
weight loss also have been reported more common with
sorafenib. However, few grade 3 and 4 adverse eﬀects have
occurred [75].
5.3.3. Vatalanib (PTK787). Being a multitargeted tyrosine
kinase inhibitor, vatalanib blocks VEGFR1-3, PDGFR-β,c -
Kit, c-Fms with highest activity against VEGFR-2. In an
ovarian cancer mouse model, single-agent vatalanib reduced
ascitesandtumorgrowthandyieldedincreasedsurvival[15].
In a phase I study of vatalanib combined with carboplatin
and paclitaxel in advanced ovarian cancer, Schroder et al.
showed that vatalanib was feasible and well tolerated [86].
The side eﬀects of vatalanib appear to be similar to those of
other VEGF inhibitors. Schroder et al. reported grade 1 and
2 hypertension as the most frequent adverse events in their
study.
5.3.4. Vandetanib (ZD6474). Vandetanib is a dual speciﬁc
inhibitor of VEGFR and EGFR. Monotherapy with vande-
tanib showed a signiﬁcant antitumor eﬀect in an ovarian
cancer nude mice model [87]. No signiﬁcant clinical beneﬁt
was made by vandetanib monotherapy in patients with
recurrent ovarian cancer in a phase II clinical trial [88].
Its eﬃcacy in combination with docetaxel in persistent or
recurrent ovarian cancer will be assessed in a phase II clinical
trial (NCT00872989) [89]. Common drug-related adverse
events include rash, diarrhea, hypertension, fatigue, and
asymptomatic QTc prolongation [90].
5.3.5. Intedanib (BIBF1120). Intedanib is a combined inhi-
bitor of VEGFR, PDGFR, and FGFR. Having potential to
block proangiogenic signaling pathways in vascular endothe-
lial cells, smooth muscle cells, and pericytes, indetanib can
inhibit cell proliferation and apoptosis. In a study by Hilberg
et al., indetanib demonstrated high activity at well-tolerated
dose as decreased vessel density and vessel integrity, and
profound growth inhibition in all tested tumor models
[91]. Ledermann et al. tested indetanib as maintenance
therapy in a randomized phase II placebo-controlled trial
in ovarian cancer patients who had previously responded to
chemotherapy and resulted in a 36-week PFS rate of 15.6%
and 2.9%, respectively, for indetanib and placebo. Thus, the
conclusion that maintenance indetanib could delay disease
progression in previously treated ovarian cancer patient was
drawn [92]. To investigate its eﬃcacy and safety, indetanib
combined with carboplatin and paclitaxel is currently being
examined in a randomized, double-blind phase III trial
in patients with advanced ovarian cancer [93]. Based on
Ledermann and colleagues’ study, the rate of gastrointestinal
toxicities was slightly higher in the indetanib arm. They also
found higher elevation of liver enzymes (43%) compared
with placebo (6.3%) [92].
5.3.6. AEE788. AEE788 is a combined VEGFR and EGFR
speciﬁc inhibitor. Although single-agent AEE788 was eﬀec-
tive in reducing tumor weight in a nude mice model of
human ovarian cancer, the combination of AEE788 and
paclitaxel was superior to the use of either agent alone,
inhibiting the progression of intraperitoneal tumor [94].
Encouraging activity was also indicated by metronomic
docetaxel chemotherapy combined with AEE788 in ortho-
topic mouse model resistant to the conventional therapy
[6, 95].
5.3.7. Pazopanib. Pazopanib is a potent and selective mul-
titargeted receptor tyrosine kinase inhibitor of VEGFR,
PDGFR, and c-Kit. Pazopanib inhibits VEGF-induced
endothelial cell proliferation in vitro and angiogenesis in
vivo and shows antitumor activity in mouse models [96].
Pazopanib alone and combined with metronomic oral
topotecanwastestedbyMerrittetal.invitroandinanortho-
topic model of ovarian cancer. Pazopanib therapy resulted
in reduced murine endothelial cell migration in a dose-
dependent manner and decreased tumor cell proliferation.
Combination therapy increased tumor cell apoptosis and
reduced tumor microvessel density and pericyte coverage
[97].AphaseIIstudyreported byFriedlanderet al.indicated
that pazopanib is active in women with advanced epithelial
ovarian cancer with overall response rate of 18% and 21%,
respectively, in subjects with and without measurable disease
at baseline. Median PFS was 84 days [98]. Several trials
of pazopanib are evaluating this agent as monotherapy or
combination with other agents [99–103].8 Journal of Oncology
5.3.8. Motesanib (AMG706). Motesanib was identiﬁed as a
potent, well-tolerated inhibitor of VEGFR 1–3 and PDGFR
in preclinical models. It also inhibits Kit receptors, thereby
directly interfering with signal transduction of the tumor cell
[104]. A phase II clinical trial of this agent in persistent or
recurrent ovarian cancer is ongoing [105].
6. Other Agents
Some agents from diﬀerent pharmacological classes have
been studied in clinical development for ovarian cancer with
possible or indirect eﬀect on VEGF or its pathway.
6.1. Thalidomide. Thalidomide was ﬁrst introduced as a
sedative drug in the late 1950s. In 1961, it was withdrawn
fromthemarketduetoitsteratogenicity[106,107],butithas
been of renewed interest as a potent angiogenesis inhibitor
which was approved by FDA [75]. Antiangiogenic and
antitumor eﬀects of thalidomide have been demonstrated
in preclinical studies [108, 109], although its mechanisms of
action are not clearly unveiled. Thalidomide may suppress
VEGF, bFGF, and TNF-α. A phase II trial of thalidomide in
some solid malignancies, including ovarian cancer, resulted
in some responses whereas a prospective randomized trial of
thalidomide with topotecan compared to topotecan alone in
women with recurrent epithelial ovarian carcinoma reported
a remarkable response with combination therapy [5]. A ran-
domized phase III trial (GOG 198) tested tamoxifen versus
thalidomide in women having the recurrence of ovarian
cancer. Thalidomide was not more eﬀective than tamoxifen
in delaying recurrence or death, but was more toxic
[110].
6.2. Atrasentan. Atrasentan is a selective antagonist of endo-
thelin type A receptor (ETAR). It reduces microvessel de-
nsity, expression of VEGF, and matrix metalloproteinase-
2, thus increases percentage of apoptotic tumor cells in
ovarian cancer xenografts. Combined with paclitaxel, atra-
sentanhasproducedadditiveantitumor,apoptotic,andanti-
angiogenic eﬀects. Fatigue, edema, and rhinitis are the most
common side eﬀects of atrasentan [9].
6.3. Everolimus. Everolimus is an inhibitor of mTOR, a
central regulating pathway of cell growth, proliferation,
and apoptosis. Inhibition of mTOR can decrease cancer
cell proliferation and survival and reduce tumor-secreted
VEGF through inhibition of hypoxia-inducible factor-1α
(HIF-1α). An in vivo study using xenograft models of
ovarian cancer revealed that everolimus inhibited tumor
growth, angiogenesis, and production of ascites, suggesting
the potential of mTOR inhibitors in the treatment of women
with ovarian cancer [9, 98].
6.4.MicrotubuleDisruptingAgents. Drugsthattargettubulin
are one of the most eﬀective classes of anticancer agents and
are thus a mainstay in the treatment of ovarian cancer [111].
Although the underlying mechanisms for the inhibition of
angiogenesis by microtubule disrupting agents (MDAs) are
not yet well deﬁned, interference with the HIF-1α/VEGF
axis seems to account for at least part, if not all, of the
eﬀects observed [112]. While the taxanes are deﬁned as
microtubulepolymerizingagents,benzimidazolecarbamates
such as albendazole are known to conversely interfere with
the polymerization process. We have recently described
how albendazole inhibits VEGF and angiogenesis under in
vitro, in vivo, and clinical conditions [113–115]. Follow-
up research revealed that the drug interferes with HIF-
1α, leading to the suppression of tumoral VEGF mRNA,
and VEGF protein [116]. Thus, irrespective of whether
a polymerizing or a depolymerising agent, the MDAs
interfere with angiogenesis and suppress VEGF production.
Treatment of mice bearing advanced intraperitoneal human
OVCAR-3 tumors with albendazole, led to suppression of
both plasma and ascites VEGF levels, as a consequence of
which highly VEGF-dependant malignant ascites formation
was completely aborted, leading to extended animal survival
[115, 117].
6.5. Celecoxib and Ciglitazone . PGE2 enhances angiogenesis
through the induction of VEGF. Celecoxib is a highly selec-
tive cyclooxygenase-2 (COX-2) inhibitor and ciglitazone is
a peroxysome proliferator-activated receptor γ (PPARγ)l i g -
and,bothinhibitingprostaglandinE2(PGE2)production.In
a preclinical ovarian cancer model, celecoxib and ciglitazone
reduced tumor growth by downregulating PGE2 synthesis
and thus inhibiting VEGF production [9]. In a phase II study
in heavily pretreated recurrent ovarian cancer patients, cele-
coxibincombinationwithcarboplatinwaswelltoleratedand
yielded promising activity as salvage treatment [118]. Cele-
coxibisalsobeingevaluatedinanongoingrandomizedphase
II study testing cyclophosphamide with or without celecoxib
[119].
7. Anti-VEGFTherapy Challenges
Besidestoxicitiesandcomplications,otherchallengesregard-
ing anti-VEGF therapy are as follows.
7.1. Resistance. Although endothelial cells are genetically
stable, emerging evidence indicates that tumor resistance to
anti-VEGF agents is common. The hypothetical rationale for
the resistance includes epigenic mechanisms of resistance,
unresponsiveness of tumor vasculature to anti-VEGF agents
[5], upregulation of alternative proangiogenic pathways,
enhanced protection by pericytes, increased invasiveness of
tumor cells into local tissue normal vasculature, metastatic
seeding, and tumor cell growth in lymph nodes and distant
o r g a n s ,a sw e l la sf a i l u r eo fa n t i - V E G Fa g e n t si nf u l l y
blocking all VEGF signaling pathways [120, 121]. Locating
additional targets on the tumor endothelium such as non-
receptor kinases, and targeting proangiogenic pathways and
agents such as HIF1-α are currently being focused to evade
the resistance [5].
7.2. Acceleration of Tumor Invasiveness and Metastasis. A
perplexing inverse eﬀect resulted from anti-VEGF therapyJournal of Oncology 9
has been found in some preclinical studies. Ebos et al.
reported:
(i) accelerated experimental metastasis, increased multi-
organ metastases, and decreased survival after short-
termsunitinibtreatmentbeforeandafterintravenous
tumor cells inoculation;
(ii) increased spontaneous metastasis and decreased sur-
vival following short-term sunitinib therapy after
removal of primary human xenograft tumors.
Acceleration of metastasis observed in mice receiving
sunitinib prior to intravenous implantation of tumor cells
suggests the possible “metastatic conditioning” eﬀect by the
mentioned anti-VEGF agent. It means microenvironmental
changes in mouse organs so that they are conditioned to be
more permissive to tumor extravasation. This study shows
similar ﬁndings with additional VEGF receptor tyrosine
kinase inhibitors, implicating a class-speciﬁc eﬀect for this
group of anti-VEGF agents [122]. Also, Paez-Ribes et al.
indicated the following:
(i) increased invasiveness and metastasis in tumor-
bearing mice treated by the VEGFR2 blocking mon-
oclonal antibody DC101;
(ii) persistent invasive phenotype after cessation of the
treatment.
SimilarresultswerereportedwithsunitinibandSU10944
administration. Paez-Ribes et al. demonstrate that these
eﬀects appear to be an adaptive/evasive response by tumor
cells themselves involving an augmented invasive phenotype
and, in some cases, increased dissemination and the emer-
gence of distant metastasis. They implicate hypoxia in the
adaptive response [123].
These studies indicate divergent eﬀects of anti-VEGF
agents on primary tumor growth and metastasis and
raise the possibility that both induction and suppression
of tumor angiogenesis can exert proinvasive/prometastatic
eﬀects [122–124].
7.3. Pharmacoeconomics. As health care costs continue to
increase, chemotherapy agents, and in particular targeted
therapies, have been scrutinized regarding the populations
in which they should be used to minimize the societal
impact of their utility. Using an intentionally oversimpli-
ﬁed cost-eﬀectiveness model comparing the three arms of
GOG218 study, Cohn et al. demonstrated that the addition
of bevacizumab to the adjuvant management of patients
with advanced ovarian cancer is not cost eﬀective and
treatment with maintenance bevacizumab, while improving
PFS, is associated with both direct and indirect costs [125].
Thus, the optimal duration of maintenance treatment with
bevacizumab will also have to be evaluated, and pharma-
coeconomic considerations will have to be addressed [9].
7.4. Other Challenges. Despite the advances, some other
critical challenges in both clinical-pathologic and preclinical
investigations are still ahead [11]. Lack of predictive markers
and accurate predictors of therapeutic eﬃcacy seems to be
a major challenge of anti-VEGF therapy in ovarian cancer
[9, 89, 126]. To date, there are no predictive biomarkers
for response to bevacizumab which means that there is no
preselection of patients who might beneﬁt from therapy
[89]. IL-8 and VEGF polymorphisms have been suggested
as potential markers of clinical outcome after bevacizumab-
based chemotherapy in refractory ovarian cancer [126].
Retrospective studies will be performed on blood and tumor
to study VEGF levels and other angiogenic markers in blood
and tumor to try and identify which patients might beneﬁt
from bevacizumab [89]. Clinically validated biomarkers
by restricting the VEGF-targeted therapy to the selected
patientswillalsoreducetherateofrelevantcomplications,in
particular gastrointestinal perforations. Since large placebo-
controlled phase III trials are still missing, well-designed
trials in which potentially important clinical eﬀects of anti-
VEGF agents are not ignored are highly required [9]. These
clinical beneﬁts may manifest as prolongation of survival,
delay in progression of disease, reduction of tumor burden,
alleviation of symptoms associated with the disease, and
minimization of toxicities associated with the treatment
of the disease [127]. Also, it has been learned that the
mere presence of a particular target does not guarantee the
therapeutic beneﬁt of the relevant targeted therapy, and,
due to the multiplicity and redundancy of the pathways,
it is unlikely that inhibition of a single cascade will be
highly eﬀective [33, 128]. A better understanding of the
relevant signaling pathways, targeting horizontal and vertical
pathways, and unveiling the underlying mechanisms of
resistance and complications are among the goals of the
future studies [11, 98].
8. Conclusion
VEGF is one of the most potent eﬀectors of physiologic and
pathologic angiogenesis. The pathophysiology of ovarian
cancer is extremely angiogenesis-dependent [9]. Highly
expressed in ovarian cancer, VEGF represents an attractive
therapeutic target and VEGF inhibitors promise to be
of signiﬁcant value in the treatment of ovarian cancer.
Preclinical and clinical studies further support the utility of
these approaches. The most promising and widely explored
bevacizumab has been used in many clinical studies either
as single agent or in combination with chemotherapy in
women with resistant or recurrent ovarian cancer. However,
lack of accurate predictors of therapeutic eﬃcacy, primary
or secondary resistance to the treatment, complications and
side eﬀects of the therapy, likely divergent eﬀects of anti-
VEGFtherapyonprimarytumorgrowthandmetastasis,and
pharmacoeconomic concerns are the major struggles in the
clinical use of VEGF inhibitors in malignancies. Some of the
goals to be targeted in future studies include improvement
in clinical trial design so that potentially important clinical
eﬀects of these agents are not ignored, a more detailed com-
prehensionofVEGFinhibitionpathwaysanddiscernmentof
optimalcombinationtherapy.Furtherinvestigationsarewar-
ranted to identify predictive biomarkers required for “indi-
vidualization” of VEGF-targeted therapy, and to precisely10 Journal of Oncology
clarify the mechanisms underlying the complications of the
treatment.
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